False-positive cannabinoid screens in adult cystic fibrosis patients treated with lumacaftor/ivacaftor.

作者信息

Kissner Dana, LeFlore Yvette, Narayan Srinivas B, Marigowda Gautham, Simard Christopher, Le Camus Cecile

机构信息

Wayne State University, Division of Pulmonary, Critical Care, and Sleep Medicine, 540 East Canfield Avenue, Detroit, MI 48201, USA.

Adult Cystic Fibrosis Center, Detroit Medical Center, 3990 John R Street, Detroit, MI 48201, USA.

出版信息

J Cyst Fibros. 2018 Nov;17(6):e51-e53. doi: 10.1016/j.jcf.2018.08.006. Epub 2018 Sep 12.

DOI:10.1016/j.jcf.2018.08.006

PMID:30217546

Abstract

摘要

相似文献

False-positive cannabinoid screens in adult cystic fibrosis patients treated with lumacaftor/ivacaftor.

J Cyst Fibros. 2018 Nov;17(6):e51-e53. doi: 10.1016/j.jcf.2018.08.006. Epub 2018 Sep 12.

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.在 F508del-CFTR 纯合子的 6-11 岁囊性纤维化患者中， lumacaftor 和 ivacaftor 的疗效和安全性：一项随机、安慰剂对照的 3 期临床试验。

Lancet Respir Med. 2017 Jul;5(7):557-567. doi: 10.1016/S2213-2600(17)30215-1. Epub 2017 Jun 9.

The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.鲁马卡托和依伐卡托治疗囊性纤维化的安全性。

Expert Opin Drug Saf. 2017 Nov;16(11):1305-1311. doi: 10.1080/14740338.2017.1372419. Epub 2017 Sep 21.

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.在囊性纤维化跨膜电导调节因子纯合子 F508del-CFTR 的 2-5 岁儿童中， lumacaftor 和 ivacaftor 联合治疗的安全性、药代动力学和药效学：一项开放标签的 3 期研究。

Lancet Respir Med. 2019 Apr;7(4):325-335. doi: 10.1016/S2213-2600(18)30460-0. Epub 2019 Jan 24.

Predictive factors for lumacaftor/ivacaftor clinical response.预测 lumacaftor/ivacaftor 临床反应的因素。

J Cyst Fibros. 2019 May;18(3):368-374. doi: 10.1016/j.jcf.2018.12.011. Epub 2018 Dec 28.

Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.鲁马卡托/依伐卡托（奥克巴胺）用于治疗囊性纤维化。

Med Lett Drugs Ther. 2016 Mar 28;58(1491):41-2.

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.评估长期使用组合 Lumacaftor 和 Ivacaftor 疗法治疗囊性纤维化纯合子 F508del-CFTR 突变患者的安全性和疗效（PROGRESS）：一项 3 期扩展研究。

Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21.

GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).GLPG2737 联合 lumacaftor/ivacaftor 治疗 F508del 纯合突变 CF 患者的 2A 期随机临床试验（PELICAN）

J Cyst Fibros. 2020 Mar;19(2):292-298. doi: 10.1016/j.jcf.2019.09.006. Epub 2019 Oct 5.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.鲁马卡托-依伐卡托用于携带苯丙氨酸508位缺失CFTR基因纯合突变的囊性纤维化患者。

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

Real-life acute lung function changes after lumacaftor/ivacaftor first administration in pediatric patients with cystic fibrosis.芦可替尼/依维莫司首次给药后小儿囊性纤维化患者的真实生活中急性肺功能变化。

J Cyst Fibros. 2017 Nov;16(6):709-712. doi: 10.1016/j.jcf.2017.05.002. Epub 2017 May 18.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验